Prof Marco Valgimigli (Istituto Cardiocentro Ticino, CH), principal investigator of the BIOFLOW-DAPT trial, discusses the design, outcomes and implications of this non-inferiority trial for 1-month DAPT regimen in high bleeding risk patients.